4.7 Article

A Novel Serum Carbohydrate Marker on Mucin 5AC Values for Diagnostic and Prognostic Indicators for Cholangiocarcinoma

Journal

CANCER
Volume 117, Issue 15, Pages 3393-3403

Publisher

WILEY-BLACKWELL
DOI: 10.1002/cncr.25912

Keywords

cholangiocarcinoma; tumor marker; enzyme-linked immunosorbent assay; carbohydrate marker; mucin; mucin 5AC

Categories

Funding

  1. Office of the Higher Education Commission
  2. National Research Council of Thailand
  3. National Research University
  4. Khon Kaen University
  5. National Genetic Engineering and Biotechnology Center
  6. National Science and Technology Development Agency, Thailand
  7. Japan Student Services Organization
  8. Ministry of Health Labor and Welfare of Japan
  9. Kurozumi Medical Foundation
  10. Founding Research Center for Emerging and Reemerging Infectious Diseases
  11. Global Centers of Excellence Program of Acquired Immunodeficiency Syndrome Research in Japan
  12. Grants-in-Aid for Scientific Research [23390122, 22021036] Funding Source: KAKEN

Ask authors/readers for more resources

BACKGROUND: The incidence of cholangiocarcinoma (CCA) is increasing globally. Currently, there is no powerful marker for the diagnosis of CCA, which has led to late diagnosis and poor patient outcome. This study was designed to establish a new monoclonal antibody (MoAb) for detecting a serum marker associated with CCA. METHODS: Pooled CCA tissue extracts were immunized to germinal center associated nuclear protein (GANP)-transgenic mice. The antibody-producing hybridomas were prepared and initially screened by using an indirect enzyme-linked immunosorbent assay (ELISA). A positive clone that reacted strongly with CCA serum or tumor tissue extract and failed to react with normal human serum and liver extract was selected. RESULTS: An S121 immunoglobulin M MoAb that recognized a novel glycan epitope was obtained. Immunohistochemistry of CCA tissues revealed that the MoAb reacted strongly with hyperplastic/dysplastic and neoplastic bile ducts but not with normal bile ducts. In addition, experiments demonstrated that mucin 5AC (MUC5AC) is a core glycoprotein for the S121 epitope. A sandwich ELISA using soybean agglutinin and an S121 MoAb was developed for detecting S121 reactive antigen in patient sera. The level of serum S121 from patients with CCA was reduced significantly after tumor removal, indicating the tumor origin of this antigen. The test was able to distinguish patients with CCA from healthy individuals, active Opisthorchis viverrini-infected individuals and patients with various gastrointestinal cancers, hepatoma, and benign hepatobiliary diseases with 87.63% sensitivity, 89.58% specificity, an 80.95% positive predictive value, and a 93.47% negative predictive value. Moreover, high serum S121 levels were related to a poor patient outcome. CONCLUSIONS: The sugar antigen recognized by S121 MoAb is a new serum marker for the diagnosis and prognosis of CCA. Cancer 2011;117:3393-403. (C) 2011 American Cancer Society

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available